Amount of qualified individuals: CDEC mentioned the uncertainty in the number of individuals with reasonably serious to serious hemophilia B in Canada qualified for etranacogene dezaparvovec. Scientific specialists consulted by CADTH indicated that some patients that are categorised as having moderate or average condition may have a severe bleeding phenotype, https://christianv246pqr9.blogdosaga.com/profile